ADMA BIOLOGICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
ADMA BIOLOGICS, INC. (ADMA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $2.03 per share for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2020-11-05
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-03-31 was $3.67.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2018-03-31 was $2.68.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2019 was $2.84, a 14.20% decline from fiscal 2018.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2018 was $3.31, a 23.51% increase from fiscal 2017.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2017 was $2.68, a 65.99% decline from fiscal 2016.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2016 was $7.88, a 20.31% increase from fiscal 2015.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2020-09-30 | $2.03 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $2.03 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | $3.67 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $2.84 10-K · filed 2020-03-13 | |||
| 2019-09-30 | $2.84 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $2.76 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $3.31 10-K · filed 2020-03-13 | |||
| 2018-09-30 | $3.14 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $2.68 10-Q · filed 2018-08-10 | |||
| 2018-03-31 | $2.68 10-Q · filed 2018-05-14 | |||
| 2017-12-31 | $2.68 10-K · filed 2019-03-13 | |||
| 2017-09-30 | $2.68 10-Q · filed 2017-11-03 | |||
| 2016-12-31 | $7.88 10-K · filed 2017-02-24 | |||
| 2016-06-30 | $7.88 10-Q · filed 2016-08-12 | |||
| 2015-12-31 | $6.55 10-K · filed 2017-02-24 | |||
| 2015-09-30 | $6.25 10-Q · filed 2015-11-10 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |